当前位置: 首页 >> 检索结果
6701. India's resurgence of COVID-19: urgent actions needed.
作者: Yamini Aiyar.;Vijay Chandru.;Mirai Chatterjee.;Sapna Desai.;Armida Fernandez.;Atul Gupta.;Gagandeep Kang.;Tarun Khanna.;Kiran Mazumdar-Shaw.;Nachiket Mor.;Arnab Mukherji.;Poonam Muttreja.;Thelma Narayan.;Bhushan Patwardhan.;K Sujatha Rao.;Sharad Sharma.;Devi Shetty.;S V Subramanian.;Leila E Caleb Varkey.;Sandhya Venkateswaran.;Vikram Patel.
来源: Lancet. 2021年397卷10291期2232-2234页 6706. A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China.
作者: Jie Qiao.;Yuanyuan Wang.;Xiaohong Li.;Fan Jiang.;Yunting Zhang.;Jun Ma.;Yi Song.;Jing Ma.;Wei Fu.;Ruyan Pang.;Zhaofang Zhu.;Jun Zhang.;Xu Qian.;Linhong Wang.;Jiuling Wu.;Hsun-Ming Chang.;Peter C K Leung.;Meng Mao.;Duan Ma.;Yan Guo.;Jie Qiu.;Li Liu.;Haidong Wang.;Robert J Norman.;Joy Lawn.;Robert E Black.;Carine Ronsmans.;George Patton.;Jun Zhu.;Li Song.;Therese Hesketh.
来源: Lancet. 2021年397卷10293期2497-2536页 6708. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Kristian Reich.;Henrique D Teixeira.;Marjolein de Bruin-Weller.;Thomas Bieber.;Weily Soong.;Kenji Kabashima.;Thomas Werfel.;Jiewei Zeng.;Xiaohong Huang.;Xiaofei Hu.;Barbara A Hendrickson.;Barry Ladizinski.;Alvina D Chu.;Jonathan I Silverberg.
来源: Lancet. 2021年397卷10290期2169-2181页
Systemic therapies are typically combined with topical corticosteroids for the management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 that is being tested for atopic dermatitis. We aimed to assess the efficacy and safety of upadacitinib plus topical corticosteroids compared with placebo for the treatment of moderate-to-severe atopic dermatitis.
6709. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
作者: Emma Guttman-Yassky.;Henrique D Teixeira.;Eric L Simpson.;Kim A Papp.;Aileen L Pangan.;Andrew Blauvelt.;Diamant Thaçi.;Chia-Yu Chu.;H Chih-Ho Hong.;Norito Katoh.;Amy S Paller.;Brian Calimlim.;Yihua Gu.;Xiaofei Hu.;Meng Liu.;Yang Yang.;John Liu.;Allan R Tenorio.;Alvina D Chu.;Alan D Irvine.
来源: Lancet. 2021年397卷10290期2151-2168页
Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and safety of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis.
6712. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study.
There have been insufficient data for African patients with COVID-19 who are critically ill. The African COVID-19 Critical Care Outcomes Study (ACCCOS) aimed to determine which resources, comorbidities, and critical care interventions are associated with mortality in this patient population.
|